NO20045589L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO20045589L
NO20045589L NO20045589A NO20045589A NO20045589L NO 20045589 L NO20045589 L NO 20045589L NO 20045589 A NO20045589 A NO 20045589A NO 20045589 A NO20045589 A NO 20045589A NO 20045589 L NO20045589 L NO 20045589L
Authority
NO
Norway
Prior art keywords
new connections
useful
treatment
relates
present
Prior art date
Application number
NO20045589A
Other languages
English (en)
Norwegian (no)
Inventor
Roger Victor Bonnert
Stephen Brough
Hitesh Sanganee
Rukhsana Tasneem Rasul
Tony Cook
Mark Dickinson
Simon Teauge
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20045589L publication Critical patent/NO20045589L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20045589A 2002-05-30 2004-12-22 Nye forbindelser NO20045589L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201635A SE0201635D0 (sv) 2002-05-30 2002-05-30 Novel compounds
PCT/SE2003/000856 WO2003101961A1 (en) 2002-05-30 2003-05-27 Novel substituted indoles

Publications (1)

Publication Number Publication Date
NO20045589L true NO20045589L (no) 2005-02-02

Family

ID=20288018

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045589A NO20045589L (no) 2002-05-30 2004-12-22 Nye forbindelser

Country Status (25)

Country Link
US (1) US7166607B2 (de)
EP (1) EP1513812B1 (de)
JP (1) JP4485354B2 (de)
KR (1) KR20050010507A (de)
CN (1) CN100404505C (de)
AR (1) AR039934A1 (de)
AT (1) ATE501118T1 (de)
AU (1) AU2003228201A1 (de)
BR (1) BR0311494A (de)
CA (1) CA2487675A1 (de)
CO (1) CO5631431A2 (de)
DE (1) DE60336314D1 (de)
ES (1) ES2360936T3 (de)
IS (1) IS7607A (de)
MX (1) MXPA04011876A (de)
MY (1) MY133624A (de)
NO (1) NO20045589L (de)
NZ (1) NZ536883A (de)
PL (1) PL375111A1 (de)
RU (1) RU2288914C2 (de)
SE (1) SE0201635D0 (de)
TW (1) TW200407305A (de)
UA (1) UA79464C2 (de)
WO (1) WO2003101961A1 (de)
ZA (1) ZA200409641B (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
NZ541234A (en) 2002-12-20 2008-06-30 Amgen Inc Asthma and allergic inflammation modulators
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
JP2007508363A (ja) * 2003-10-14 2007-04-05 オキサジェン リミテッド Crth2アンタゴニスト活性を有する化合物
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7714132B2 (en) 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
JP2008500991A (ja) 2004-05-29 2008-01-17 7ティーエム ファーマ エイ/エス 医学的使用のためのcrth2レセプターリガンド
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
CA2577748A1 (en) * 2004-08-26 2006-03-02 Actelion Pharmaceuticals Ltd 2-sulfanyl-benzoimidazol-1-yl-acetic acid derivatives as crth2 antagonists
JP2008513512A (ja) 2004-09-21 2008-05-01 アサーシス, インク. Crth2受容体拮抗作用を示すインドール酢酸およびこれらの使用
PT1809602E (pt) * 2004-10-27 2008-12-15 Janssen Pharmaceutica Nv Derivados de indole úteis como moduladores do receptor da progesterona
ATE517085T1 (de) 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
ES2369782T3 (es) 2004-12-27 2011-12-05 Actelion Pharmaceuticals Ltd. Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2.
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Pgd2受容体アンタゴニスト活性を有するアザインドール酸誘導体
US7956082B2 (en) 2005-07-22 2011-06-07 Shionogi & Co., Ltd Indole derivative having PGD2 receptor antagonist activity
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007039736A1 (en) 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
GB0521275D0 (en) * 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
GB0524428D0 (en) 2005-11-30 2006-01-11 7Tm Pharma As Medicinal use of receptor ligands
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
HUE030850T2 (en) 2006-06-16 2017-06-28 Univ Pennsylvania Prostaglandin D2 receptor antagonists for the treatment of hair loss
WO2008012511A1 (en) 2006-07-22 2008-01-31 Oxagen Limited Compounds having crth2 antagonist activity
MY147588A (en) 2006-08-07 2012-12-31 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
US20100137300A1 (en) * 2007-03-21 2010-06-03 George Hynd Indolizine Acetic Acid Derivatives as CRTH2 Antagonists
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
NZ585888A (en) 2007-12-14 2012-02-24 Pulmagen Therapeutics Asthma Ltd Indoles and their therapeutic use
WO2009085177A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Phenyl acetic acid derivatives as inflammation modulators
RS53142B (sr) 2008-01-18 2014-06-30 Atopix Therapeutics Limited Jedinjenja koja imaju antagonističku aktivnost na crth2
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
US8168673B2 (en) 2008-01-22 2012-05-01 Oxagen Limited Compounds having CRTH2 antagonist activity
US20100022613A1 (en) 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity
WO2011055270A1 (en) 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
US8674115B2 (en) 2009-12-23 2014-03-18 Ironwood Pharmaceuticals, Inc. CRTH2 modulators
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CA2790139C (en) 2010-03-22 2018-03-13 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
WO2012003405A1 (en) 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
NZ609955A (en) 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
JP5964945B2 (ja) 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 7−(ヘテロアリ−ル−アミノ)−6,7,8,9−テトラヒドロピリド[1,2−a]インド−ル酢酸誘導体及びプロスタグランジンD2受容体調節剤としてのそれらの使用
WO2012158435A1 (en) * 2011-05-17 2012-11-22 Han-Jie Zhou Compositions and methods for jamm protein inhibition
KR20140113667A (ko) 2011-12-16 2014-09-24 아토픽스 테라퓨릭스 리미티드 호산구성 식도염의 치료를 위한 crth2 길항제 및 양성자 펌프 저해제의 조합
KR101939710B1 (ko) 2011-12-21 2019-01-17 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
CN104066731B (zh) 2011-12-27 2016-06-15 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
CN104602763B (zh) 2012-03-21 2018-08-21 宾夕法尼亚大学理事会 用于调节毛发生长的组合物和方法
UY34993A (es) 2012-08-28 2014-02-28 Janssen R & D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CN104797561B (zh) * 2012-08-28 2017-03-01 爱尔兰詹森科学公司 稠合二环的氨磺酰基衍生物及其作为药物用于治疗乙型肝炎的用途
US9309235B2 (en) 2012-09-18 2016-04-12 Ironwood Pharmaceuticals, Inc. SGC stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
WO2014131847A1 (en) 2013-02-28 2014-09-04 Janssen R&D Ireland Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
SI2970243T1 (sl) 2013-03-15 2020-04-30 Cyclerion Therapeutics, Inc. SGC stimulatorji
JP6419155B2 (ja) 2013-04-03 2018-11-07 ヤンセン・サイエンシズ・アイルランド・ユーシー N−フェニル−カルボキサミド誘導体およびb型肝炎を治療するための医薬品としてのその使用
JO3583B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
NO3024819T3 (de) 2013-07-25 2018-07-21
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
EP3092231B1 (de) 2013-12-11 2018-06-27 Ironwood Pharmaceuticals, Inc. Sgc-stimulatoren
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
EP3094327A1 (de) 2014-01-13 2016-11-23 Ironwood Pharmaceuticals, Inc. Verwendung von sgc-stimulatoren zur behandlung von neuromuskulären störungen
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
WO2015120178A1 (en) 2014-02-05 2015-08-13 Novira Therapeutics, Inc. Combination therapy for treatment of hbv infections
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
CA2939892C (en) 2014-03-17 2020-03-31 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CN106103437A (zh) 2014-03-18 2016-11-09 埃科特莱茵药品有限公司 氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Crth2拮抗劑化合物及其用途
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
CA2961489A1 (en) 2014-09-17 2016-03-24 Glen Robert RENNIE Sgc stimulators
CA2959757A1 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
WO2016128565A1 (en) 2015-02-13 2016-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
HK1247147A1 (zh) 2015-03-19 2018-09-21 诺维拉治疗公司 氮杂环辛烷和氮杂环壬烷衍生物以及治疗乙型肝炎感染的方法
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017019858A1 (en) 2015-07-30 2017-02-02 The Trustees Of The University Of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2
CN108026093B (zh) 2015-09-15 2021-11-16 爱杜西亚药品有限公司 结晶形式
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
BR112019000293A2 (pt) 2016-07-07 2019-04-16 Ironwood Pharmaceuticals, Inc. formas sólidas de um estimulador de sgc
KR102513343B1 (ko) 2016-07-07 2023-03-22 사이클리온 테라퓨틱스, 인크. sGC 자극제의 인 전구약물
JP2021515769A (ja) 2018-03-14 2021-06-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合調節剤の投薬レジメン
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法
CN114989136A (zh) * 2021-02-02 2022-09-02 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
WO2022166638A1 (zh) * 2021-02-02 2022-08-11 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
CN114835678A (zh) * 2021-02-02 2022-08-02 广东东阳光药业有限公司 吲哚衍生物的盐及其用途
CN115093360B (zh) * 2022-07-06 2023-11-17 都创(上海)医药科技股份有限公司 一种吲哚类衍生物的合成方法
CN117205206A (zh) * 2023-08-16 2023-12-12 江南大学 一种能改善哮喘小鼠病理特征的色氨酸代谢物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) * 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPS5239671A (en) * 1975-09-22 1977-03-28 Sankyo Co Ltd Process for preparing indole-3-thioether compounds
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) * 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
WO1994016687A1 (en) 1993-01-28 1994-08-04 The Trustees Of The University Of Pennsylvania Use of creatine or analogs for the manufacture of a medicament for inhibiting tumor growth
JPH08507067A (ja) * 1993-02-24 1996-07-30 メルク エンド カンパニー インコーポレーテッド Hiv逆転写酵素阻害剤
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
AU9025898A (en) 1997-08-21 1999-03-08 American Home Products Corporation Solid phase synthesis of 2,3-disubstituted indole compounds
AU2201699A (en) 1997-12-19 1999-07-12 Eli Lilly And Company Hypoglycemic imidazoline compounds
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
WO2001032621A1 (en) 1999-10-29 2001-05-10 Wakunaga Pharmaceutical Co., Ltd. Novel indole derivatives and drugs containing the same as the active ingredient
EP1990343B1 (de) 1999-12-24 2012-04-04 Aventis Pharma Limited Azaindole
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
EP1501826B1 (de) 2002-02-01 2006-09-27 F. Hoffman-la Roche AG Substituierte indole als alpha-1 agonisten
WO2003097598A1 (en) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
AU2003228201A1 (en) 2003-12-19
JP4485354B2 (ja) 2010-06-23
ATE501118T1 (de) 2011-03-15
CA2487675A1 (en) 2003-12-11
MY133624A (en) 2007-11-30
CN1671659A (zh) 2005-09-21
UA79464C2 (en) 2007-06-25
BR0311494A (pt) 2005-03-29
SE0201635D0 (sv) 2002-05-30
KR20050010507A (ko) 2005-01-27
TW200407305A (en) 2004-05-16
RU2004135064A (ru) 2005-08-10
RU2288914C2 (ru) 2006-12-10
US7166607B2 (en) 2007-01-23
CN100404505C (zh) 2008-07-23
ZA200409641B (en) 2006-02-22
MXPA04011876A (es) 2005-03-31
DE60336314D1 (de) 2011-04-21
NZ536883A (en) 2006-08-31
AR039934A1 (es) 2005-03-09
US20050165055A1 (en) 2005-07-28
IS7607A (is) 2004-12-21
EP1513812B1 (de) 2011-03-09
CO5631431A2 (es) 2006-04-28
PL375111A1 (en) 2005-11-28
JP2005538955A (ja) 2005-12-22
WO2003101961A1 (en) 2003-12-11
EP1513812A1 (de) 2005-03-16
ES2360936T3 (es) 2011-06-10

Similar Documents

Publication Publication Date Title
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
SE0202241D0 (sv) Novel Compounds
SE0201635D0 (sv) Novel compounds
EA200601798A1 (ru) Замещенные соединения морфолина для лечения расстройств центральной нервной системы
JO2764B1 (en) Indole derivatives or benzimidazole derivatives to modify the enzyme AKP kinase
NO20055219L (no) Nye forbindelser
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
NO20073665L (no) 2-fenoksy-N-(1,3,4-tiadizol-2-yl) Pyridin-3-aminderivater og beslektede forbindelser som P2Y1 reseptor inhibitorer for behandling av tromboemboliforstyrrelser
NO20070855L (no) Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer.
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
CY1111977T1 (el) Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
SE0301009D0 (sv) Novel compounds
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
ATE447575T1 (de) Selektive spirocyclische glucocorticoid-rezeptor- modulatoren
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
NO20060718L (no) Substituerte tiofoner og deres anvendelse
EA200602083A1 (ru) Новые пиперазиновые производные диалкилоксиндолов

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application